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Summary
Bz-423 is a 1,4-benzodiazepine that suppresses dis-
ease in lupus-prone mice by selectively killing patho-
genic lymphocytes, and it is less toxic compared to
current lupus drugs. Cells exposed to Bz-423 rapidly
generate O2− within mitochondria, and this reactive
oxygen species is the signal initiating apoptosis.
Phage display screening revealed that Bz-423 binds
to the oligomycin sensitivity conferring protein
(OSCP) component of the mitochondrial F1F0-ATPase.
Bz-423 inhibited the F1F0-ATPase in vitro, and recon-
stitution experiments demonstrated that inhibition
was mediated by the OSCP. This target was further
validated by generating cells with reduced OSCP ex-
pression using RNA interference and studying the
sensitivity of these cells to Bz-423. Our findings help
explain the efficacy and selectivity of Bz-423 for auto-
immune lymphocytes and highlight the OSCP as a
target to guide the development of novel lupus thera-
peutics.
Introduction
The autoimmune disorder systemic lupus erythemato-
sus (SLE) afflicts up to 1,000,000 Americans [1]. The
central immunologic disturbance of SLE is the loss of
B and T cell peripheral tolerance [2], and the resulting
pathology is characterized by nonspecific inflammation
in a variety of tissues and organs, including the kidney,
where immune complex deposition and abnormal cellu-
lar proliferation can lead to renal failure [3]. The cause
of SLE is unknown, and disease susceptibility appears
to be influenced by multiple genes and environmental
factors [4]. Currently, SLE treatment is empirical and
employs anti-inflammatories, antimetabolites, and im-
munosuppressives that affect both pathogenic and
normal cells [5, 6]. While patient survival has improved
over the past 50 years, the morbidity from both the dis-
ease and therapy remains significant. Agents that act
more specifically against lupus-determining lymphoid
cells would represent a key advance in the treatment
of SLE and related autoimmune disorders.
A principal difficulty in developing new therapies for
SLE is the lack of cogent molecular targets for pharma-
cological intervention [5]. Autoreactive lymphocytes*Correspondence: aopipari@umich.edu (A.W.O.); gglick@umich.
edu (G.D.G.)compose only a small percentage of the total lympho-
cyte repertoire in SLE, and the molecular basis for their
autoreactivity and pathogenicity is largely unknown [2].
In the absence of molecular targets, diversity-oriented
synthesis coupled to phenotype screening is a power-
ful method for identifying new, biologically active com-
pounds [7]. Using this approach, we recently discov-
ered a 1,4-benzodiazepine (Bz-423, Figure 1A) that
induces apoptosis in lymphoid cells. When adminis-
tered to lupus-prone autoimmune (NZB × NZW)F1
(NZB/W) [8] and MRL/MpJ-Faslpr (MRL-lpr) mice [9],
Bz-423 specifically induced apoptosis in pathogenic
lymphocytes, attenuated disease progression, and pro-
longed survival. In NZB/W mice, activated germinal
center (GC) B cells were killed, whereas activated sple-
nic CD4+ T cells were targeted in the MRL-lpr strain.
Unlike current anti-lupus drugs, the therapeutic dosage
of Bz-423 suppressed autoimmune disease without
adverse toxicity or suppression of normal immune
function.
Subcellular fractionation studies revealed that Bz-
423 acts directly on mitochondria, rapidly inducing su-
peroxide (O2−) from the mitochondrial respiratory chain
(MRC) [8]. This reactive oxygen species (ROS) functions
as the key signal to initiate the permeability transition
(PT), cytochrome c release, and apoptosis. These con-
clusions were based on experiments showing that: Bz-
423 produced a dose-dependent increase in O2−; the
amount of apoptosis produced by a given [Bz-423] is
directly proportional to the amount of O2− induced; and
antioxidants like vitamin E or the manganese superox-
ide dismutase mimetic, manganese(III)meso-tetrakis(4-
benzoic acid)porphyrin (MnTBAP), blocked all down-
stream events leading to and including cell death [8].
The O2− response only occurred within coupled,
actively respiring mitochondria (i.e., state 3), which is
characteristic of F1F0-ATPase inhibitors [10]. Blocking
the activity of this enzyme during active respiration
places mitochondria in state 4 (a resting state), which
leaves the MRC in a reduced form that favors reduction
of O2 to O2− at MRC complex III. Importantly, the O2−
response was also observed in the lymphoid tissue of
mice dosed with Bz-423, linking this mechanism to the
therapeutic response [8].
Based on the properties of Bz-423 and its therapeutic
potential, a series of experiments was conducted to
identify and characterize its subcellular target. We find
that Bz-423 inhibits the mitochondrial F1F0-ATPase
both in isolated mitochondrial preparations and in
whole cells, and inhibition is mediated by the oligomy-
cin sensitivity conferring protein (OSCP) subunit of the
enzyme, a component for which limited structural, bio-
chemical, and mechanistic information is available [11].
Recent studies suggest that lupus lymphocytes have
increased numbers of mitochondria, and these mito-
chondria have altered bioenergetic and redox proper-
ties that would sensitize them to an F1F0-ATPase inhibi-
tor like Bz-423 [12–14]. Collectively, these studies
validate the mitochondrial F F -ATPase as a drug target1 0
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rfor SLE and suggest that molecules like Bz-423 are
wpromising leads.
a
nResults
q
FBz-423 Binds to the OSCP and Inhibits
tthe Mitochondrial F1F0-ATPase In Vitro
(Previous studies demonstrated that Bz-423-induced
mitochondrial O2− is the second messenger initiating
qapoptosis in response to this agent, which suggested
Othat a mitochondrial redox enzyme might be the molec-
ular target of Bz-423. However, treating cells with inhib-
Fitors of the MRC enzymes or inhibitors of other redox
Iproteins did not block the action of Bz-423, arguing
dagainst this hypothesis. Next, we investigated the in-
ovolvement of >40 upstream molecular targets that
Ocould trigger proapoptotic signaling pathways in lym-
iphocytes using both whole cell and in vitro screens
c(e.g., kinases; phosphatases; H+, K+/Na+, and Ca2+-
pATPases; ion transporters; ion channels; redox en-
Ozymes; death receptors; caspases; Bcl-2 family mem-
gbers; and components of the permeability transition
O(PT) pore). These studies failed to identify the target of
FBz-423 responsible for apoptosis.
fAs an alternative approach, an immobilized biotiny-
Flated analog of Bz-423 was used to screen a human
tcDNA T7 phage display library for the target [15]. After
five successive rounds of selection and amplification,
20 phage clones were randomly selected and their in- B
Fserts sequenced. Nine unique sequences were ob-
tained, four of which had database matches. Only one Aw
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Figure 1. Structure and Target of Bz-423
(A) Chemical structure of Bz-423 (R = CH3) and Bz-423-biotin con-
tjugate [R = (CH2)6NH-biotin]. Bz-423 does not bind to GABA recep-
mtors and therefore is not anxiolytic, and binding to the peripheral
benzodiazepine receptor (PBR) is weak (Kd > 1 M). The biotin o
linker does not alter the cytotoxic activity of Bz-423. m
(B) Phage display selects the OSCP. Semiquantitative PCR using z
primers specific for the OSCP sequence reveals enrichment of
dclones encoding the OSCP with each round of selection using im-
Fmobilized Bz-423. The cloned fragment represents 85% of the full-
hlength protein.of these clones contained a cDNA that was in-frameith the C10 phage coat protein—this cDNA contained
he coding region for amino acids 27–202 of the OSCP
Figure 1B).
The OSCP is part of a peripheral stalk that links the
ntegral membrane F0 component of the mitochondrial
1F0-ATPase with its soluble catalytic F1 domain [16].
his 213 amino acid long protein (including the 23
mino acid mitochondrial leader sequence) is highly
onserved among mammals and is not present in other
TPases. To determine if Bz-423 affected the enzymatic
ctivity of the F1F0-ATPase, submitochondrial particles
SMPs) were prepared from bovine heart and treated
ith Bz-423, and F1F0-ATPase activity was evaluated.
z-423 inhibited both the synthetic and hydrolytic
ctivities of this enzyme (Figure 2A). Neither PK11195,
benzodiazepine analog that binds tightly to the
eripheral benzodiazepine receptor (PBR) [17], nor di-
zepam, which binds γ-aminobutyric acid (GABA) re-
eptors in the central nervous system, had any effect,
emonstrating that the ability of Bz-423 to inhibit the
1F0-ATPase distinguishes it from other known benzo-
iazepines. F1F0-ATPase inhibition kinetics revealed
hat Bz-423 affects both Vmax and Km, whereas oligo-
ycin, which blocks proton transport in F0 [18], affects
nly Vmax (Figure 2B). These data demonstrate that the
echanisms by which these compounds inhibit the en-
yme are different; while the full implications of these
ifferences are still being explored, they predict that
1F0-ATPase inhibition by Bz-423 and oligomycin will
ave different consequences in vivo.
To determine whether the OSCP was required for Bz-
23-mediated F1F0-ATPase inhibition, we purified and
econstituted different portions of the ATPase, with and
ithout the OSCP. F1 can be solubilized away from F0
nd the peripheral stalk and retain its hydrolytic (but
ot synthetic) function [19]. F0 can be obtained by se-
uentially depleting SMPs of the inhibitor protein (IF1),
1, and the OSCP, yielding SMPs [20]. Purified F1 can
hen be reconstituted with recombinant OSCP alone
F1•OSCP), SMPs alone (F1•SMPs), or OSCP and
SMPs (F1•OSCP•SMPs) [21]. If the OSCP was re-
uired for inhibition, enzyme preparations lacking the
SCP should be insensitive to Bz-423.
Bz-423 inhibited the hydrolytic activity of purified
1•OSCP complexes and F1•OSCP•SMPs (Figure 3A).
n contrast, Bz-423 did not significantly inhibit ATP hy-
rolysis by purified F1 and had a small effect (ca. 30%)
n F1•SMPs, which likely resulted from the residual
SCP still present in the SMPs (Figure 3B, lane 4; it
s not possible to fully remove the OSCP through bio-
hemical depletion [20]). This conclusion is further sup-
orted by the fact that oligomycin, which requires the
SCP to inhibit hydrolysis, inhibited F1•SMPs to a de-
ree identical to that seen with Bz-423 (10 M). The
SCP makes contacts with both F0 and F1, and it binds
1•SMPs much more tightly than F1 alone [22]. There-
ore, the difference in the potency of Bz-423 against
1•OSCP versus F1•OSCP•SMPs probably reflects
he reduced stability of the F1•OSCP complex.
z-423 Inhibits the Mitochondrial
1F0-ATPase in Cells
series of experiments was performed to determine ifthe effects of Bz-423 on living cells were consistent
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487Figure 2. Bz-423 Inhibits the F1Fo-ATPase
(A) Bovine SMPs were treated with Bz-423, and rates of ATP synthesis (filled bars) and hydrolysis (open bars) were determined using NADP+
and NADH-coupled assays, respectively. Oligomycin (oligo; 0.1 M) and efrapeptin (efrapep; 1 M) are known F1Fo-ATPase inhibitors. PK =
PK11195 (10 M); and DZ = diazepam (10 M). The ATP synthesis and hydrolysis activities of the SMPs were 0.2 and 0.9 mol/min/mg
protein, respectively, in the absence of inhibitors. None of the inhibitors affected the activity of the coupling enzymes used in either assay.
(B) Double reciprocal plot of ATP hydrolysis activity in SMPs. Inhibition by Bz-423 (left; vehicle control [closed diamonds]; Bz-423: 5 [open
circles], 7.5 [closed triangles], 10 [open triangles], 15 [closed circles] M) compared to oligomycin (right; control [closed diamonds]; oligomy-
cin: 10 nM [open circles], 25 nM [closed triangles], 50 nM [open triangles], 100 nM [closed circles]).
Error bars represent the standard deviation from at least three separate determinations.with inhibition of the F1F0-ATPase. Because inhibition
of the F1F0-ATPase prevents proton flow from the inter-
membrane space back into the mitochondrial matrix
[23], F1F0-ATPase inhibitors hyperpolarize the mito-
chondrial membrane potential (MMP) [24]. Thus, we
sought to examine the effect of Bz-423 on the MMP in
Ramos cells, a Burkitt’s lymphoma cell line with a GC
phenotype [25] in which most of the mechanistic data
on Bz-423 has been obtained [8, 26]. MMP was moni-
tored using the potentiometric fluorescent dye, 3,3#-
dihexyloxacarbocyanine iodide (DiOC6(3)), which accu-
mulates in mitochondria of living cells. MMP hyperpo-
larization was observed after 1 hr of treatment with
either Bz-423 or oligomycin (Figure 4A). In contrast,
antimycin A, which inhibits complex III [27], or betulinic
acid, which binds to the mitochondrial PT pore [28], did
not increase the MMP. To examine the effect of Bz-423on mitochondrial ATP synthesis, digitonin-permeabi-
lized Ramos cells were treated with Bz-423 and the rate
of ATP synthesis was measured [29]. Bz-423 inhibited
ATP synthesis in a concentration-dependent manner
with an IC50 similar to the EC50 for apoptosis in these
cells (ca. 5 M [8]; Figure 4B).
In coupled, actively respiring mitochondria (i.e., state
3, ADP present), F1F0-ATPase inhibitors induce a transi-
tion back to resting levels of respiration (known as state
4) [10]. The critical signal orchestrating apoptosis in re-
sponse to Bz-423 is O2−. Our data indicate that this O2−
results from a state 3 to 4 transition produced as a re-
sult of Bz-423 inhibiting the F1F0-ATPase. To test this
hypothesis directly, digitonin-permeabilized Ramos
cells were treated with malate/glutamate as energy
sources along with ADP [30], and the rate of O con-2
sumption was monitored as a function of [Bz-423]. After
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Figure 3. Bz-423 Binds the OSCP t
(A) Effect of Bz-423 on F1 (top) and F1,SMPs (bottom) in the pres- c
ence (open bars) and absence (filled bars) of the OSCP. Contrast p
the inhibitory pattern of Bz-423 with the F1 inhibitor, efrapeptin a(efrapep; 1 M), that inhibited all preparations, and the F0 binding
winhibitor, oligomycin (oligo; 0.1 M), that required both the OSCP
fand SMPs for inhibition. The ATP hydrolysis activity of isolated F1
was ca. 10 mol/min/mg protein (in the absence of inhibitors). t
(B) Western blot analysis of OSCP levels at each step of SMP w
preparation. Lane 1, starting SMPs; lane 2, SMPs lacking IF1; lane a
3, SMPs lacking IF1 & F1; lane 4, SMPs lacking IF1, F1, and OSCP o
(SMPs). GAPDH was used as a protein loading control.
cError bars represent the standard deviation from at least three sep-
larate determinations.
5
w
the addition of 0.045 moles of Bz-423, the rate of O2 t
consumption began to decrease significantly (from 18.5
to 14.8 nmol O2/min/30 × 106 cells; Figure 4C). To en- s
sure this change did not merely result from depletion of r
the ADP supply, more ADP (200 mol) was added; the g
rate did not increase, confirming the presence of suffi- m
cient [ADP]. Addition of more Bz-423 continued to de- b
crease the rate of O2 consumption, until the rate de- t
creased to that observed under state 4 conditions after l
0.090 moles total of drug was added. Collectively, this (
5set of studies demonstrates that, in cells, Bz-423 inhib-ts the F1F0-ATPase, and as shown below, this activity
ediates its proapoptotic effects.
The OSCP couples proton translocation in F0 to ca-
alysis in F1 and is therefore required for mitochondrial
TP synthesis [31, 32]. Not surprisingly, yeast OSCP
nockouts fail to survive under normal growth condi-
ions [33]. Thus, we expected that knocking out the
SCP in mammalian cells would similarly be lethal. To
emonstrate that the OSCP mediates Bz-423-induced
poptosis, the relationship between levels of OSCP and
ensitivity to Bz-423 was investigated using RNA inter-
erence (RNAi) [34]. Decreasing drug target levels can
ither sensitize or protect against death by target-spe-
ific agents. If target binding by a drug interferes with
he ability of that target to provide a growth/survival
ignal or critical metabolite, then decreasing the level
f target will sensitize cells to death induced by the
gent. This occurs because a constant amount of inhib-
tor more completely saturates and more completely in-
ibits the function of the smaller number of target sites
vailable for drug binding (e.g., inhibition of thymidylate
ynthase [35]). However, if target binding by a drug in-
tead causes the target to generate increased levels of
death-inducing signal, decreasing the level of target
ill protect cells against death induced by that agent
ecause a given drug will not generate as much of the
eath signal (small molecules that bind to the X-linked
nhibitor of apoptosis (XIAP) are example of this mode
ction [36]). Since Bz-423 initiates cell death by gener-
ting O2−, we predicted that, at a given [Bz-423], cells
ith less OSCP would produce less O2− (the death sig-
al) and would consequently be protected from Bz-
23-induced cell death. Only with a very significant
SCP reduction (i.e., to levels close to knockout) would
e predict cells to be more sensitive to Bz-423, as the
emaining functional F1F0-ATPases would not be able
o provide enough ATP for normal cellular function in
he presence of Bz-423.
To test this hypothesis, 293 cells were transiently
ransfected with siRNAs against the OSCP or with a
ontrol sequence not in the human genome. OSCP ex-
ression was analyzed by immunoblotting at 24, 48, 72,
nd 96 hr after transfection. Maximum OSCP reduction
as observed at 72 hr (Figure 4D, inset; siRNA 2); there-
ore, cells were treated with Bz-423 beginning 72 hr af-
er transfection. Consistent with our hypothesis, cells
ith less OSCP were less sensitive to Bz-423-induced
poptosis than control cells (Figure 4D). The sensitivity
f the transfectants to Bz-423-induced apoptosis
orrelated with the amount of OSCP remaining; OSCP
evels in cells transfected with siRNAs 1 and 2 were
5% and 35% of that in control cells, and when treated
ith 10 M Bz-423 the transfectants had 64% and 44%
he death of the controls, respectively.
Because OSCP levels recover 96 hr following tran-
ient transfection, stably transfected 293 cells with
educed OSCP levels (δOSCP, clones 1 and 2) were
enerated for further analysis (Figure 5A). Since mam-
alian cells with reduced OSCP expression have not
een reported, we first characterized the properties of
he mitochondria in the δOSCP clones. Reducing OSCP
evels did not alter expression of the MRC enzymes
data not shown) or other F1F0-ATPase subunits (Figure
A) and had no effect on mitochondrial ultrastructure
Drug Target for Systemic Autoimmunity
489Figure 4. Bz-423 Inhibits the F1F0-ATPase in Cells and Induces Cell Death via OSCP Binding
(A) Analysis of MMP in Ramos cells. Cells were treated with Bz-423 (Bz; M), oligomycin (oligo; 1 M), betulinic acid (Bet A; 20 M), antimycin
A (AA; 10 M), or the protonophore, CCCP (50 M), that abolishes the MMP, for 1 hr, and stained with DiOC6(3). The fluorescence intensity in
vehicle control (dashed lines) and treated cells (solid lines) was measured by flow cytometry.
(B) Rate of ATP synthesis in Ramos cells. Cells were permeabilized with digitonin, ADP and malate/glutamate substrates were added, and
cells were then treated with Bz-423 or oligomycin (oligo; 0.1 M). The rate of ATP synthesis was measured using a luciferase-luciferin reporter
assay, and RLU was converted to [ATP] using an ATP standard curve. RLU values were corrected for the small amount of luciferase
inhibition observed with Bz-423; oligomycin does not affect luciferase activity.
(C) O2 consumption in Ramos cells. Cells (30 × 106) were permeabilized with digitonin, placed in a sealed chamber, malate/glutamate (5 mM)
and ADP (mol) substrates were added as indicated, and the effect of Bz-423 on the rate of oxygen consumption was monitored. Rates (nmol
O2/min/30 × 106 cells) are indicated in parentheses under the trace. EtOH alone (1% final concentration) does not inhibit O2 consumption. The
total amount of Bz-423 used in this experiment corresponds to 0.003 moles/106 cells/ml, which are typical conditions under which the
proapoptotic effects of Bz-423 are observed. The rate of O2 consumption in Ramos cells prevented the use of fewer cells in the assay.
(D) PI permeability (cell death) of 293 cells transiently transfected with 21 bp long siRNAs specific for the OSCP or control sequence and
treated with vehicle control or Bz-423: control (black bars), siRNA 1 (white), and siRNA 2 (gray). Inset shows Western blot analysis of OSCP
levels in transient transfectants: control (c), siRNA 1 (1; 45% decrease in OSCP), and siRNA 2 (2; 65% decrease). β-tubulin was used as a
protein-loading control.
Error bars represent the standard deviation from at least three separate determinations.(Figure 5B). These latter findings are important since
certain genetic changes that affect the F1F0-ATPase
can drastically alter mitochondrial structure and func-
tion [37].
The impact of reducing OSCP levels on the MMP andnumber of mitochondria was evaluated using confocal
microscopy analysis of cells stained with DiOC6(3),
which provides an estimate of MMP, and MitoTracker
Red 580, which stains mitochondria independent of
MMP. MitoTracker Red and DiOC (3) staining coloca-6
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(A) Western blot of F1F0-ATPase subunits in clones 1 (70% OSCP reduction) and 2 (40% OSCP reduction). The mitochondrial levels of other
F1F0-ATPase subunits (α, β, d) did not change. β-tubulin was used as a protein-loading control.
(B) Electron micrographs of mitochondria in control transfectants (left) and clone 1 (right) (19,600× magnification).
(C) Qualitative analysis of the MMP and number of mitochondria in the clones. Control cells (top) and clones 1 (middle) and 2 (bottom) were
coloaded with MitoTracker Red 580 (red stains; mitochondria independent of MMP) and DiOC6(3) (green; MMP-dependent staining), and
images were obtained using fluorescent confocal microscopy. The MitoTracker Red and DiOC6(3) staining colocalized in all cells, and was
indistinguishable between the clones and controls. Each image is representative of three separate experiments.
(D) Quantitative analysis of mitochondria in the clones. Cells were stained with DiOC6(3) and MitoTracker Red, and the mean fluorescence
intensity was measured by flow cytometry. δOSCP clones 1 (thick solid line) and 2 (thin solid line) had very similar MMPs and an indistinguish-
able number of mitochondria versus control cells (dashed line). CCCP (50 M) treatment demonstrates that DiOC6(3) fluorescence is MMP-
dependent, while MitoTracker Red fluorescence remains regardless of MMP. The GFP signal in the transfectants is >20-fold weaker than the
DiOC6(3) staining and did not interfere with analysis here or in (C).lized in the δOSCP clones, and the fluorescence of con- d
strol cells and δOSCP clones was indistinguishable (Fig-
ure 5C). Quantitative analysis by flow cytometry o
sdemonstrated that the mean fluorescence intensity of
both MitoTracker Red and DiOC6(3) was nearly identical c
din the δOSCP clones and control cells (Figure 5D), con-sistent with the imaging data. Since these experimentsemonstrate that reducing OSCP expression does not
ignificantly affect the structure, membrane potential,
r number of mitochondria, any differences in the re-
ponses of the δOSCP clones to Bz-423 compared to
ontrol cells should be directly attributable to the re-
uced OSCP levels.
Both δOSCP clones were less sensitive to Bz-423
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491than control cells, and like the transient transfectants,
their levels of OSCP expression correlated with their
sensitivity to Bz-423 (Figure 6A). Specifically, the OSCP
level in clones 1 and 2 was 30% and 60% of that in
control cells, and when treated with 11 M Bz-423 (near
the EC50 for the control cells), the clones had 39% and
84% the death of controls. In contrast, decreasing
OSCP expression did not affect sensitivity to a range
of other cytotoxic drugs, including the DNA damaging
agents, cis-diaminodichloroplatinum (CDDP) and eto-
poside; the kinase inhibitor, staurosporine; the MRC
poisons, antimycin A and N-(4-hydroxyphenyl)retinam-
ide (4-HPR); and betulinic acid, which directly triggers
the PT pore (Figure 6A). These results show that
decreasing OSCP expression specifically attenuates
the cytotoxic response to Bz-423.
To determine if the mechanism of cell death in the
δOSCP clones changed relative to control cells, the me-
diators of Bz-423-induced apoptosis were examined.
The δOSCP clones generated O2− (Figure 6B) and en-
gaged the same downstream death pathways over the
same time course as controls (e.g., collapse of the
MMP, cytochrome c release, caspase activation; data
not shown), despite requiring higher [Bz-423] to pro-
duce equivalent responses. At a given [Bz-423], O2−
production in each clone correlated with its OSCP level;
clone 2 had more OSCP and generated more O2− than
clone 1, while control cells had the highest levels of
OSCP and the largest O2− response (Figure 6B). In ac-
cordance with this observation, the degree of inhibition
of state 3 respiration at a given [Bz-423] also correlated
with the level of OSCP and O2− response (data not
shown). When cell death was plotted versus O2− as a
function of [Bz-423], the curves for the control and
clone 1 had similar shapes (Figure 6C), suggesting that
the O2− response was equally as important for initiating
apoptosis in the clones as controls. Moreover, in both
the clones and controls, the percentage of cells stain-
ing O2− positive at 1 hr predicted the level of cell death
at 24 hr across a range of [Bz-423]. For example, when
treated with 11 M Bz-423, the percentage of O2− posi-
tive controls and clones 1 and 2 was 57, 20, and 47%,
respectively. After 24 hr, the percentage of dead cells
was 57, 22, and 48%. Additionally, the antioxidants, vi-
tamin E and MnTBAP, blocked Bz-423-induced O2− and
apoptosis as effectively in δOSCP clones as in controls
(Figure 6C). These results argue that OSCP expression
determines the initial response to Bz-423 (i.e., O2− gen-
eration) and the clones use the same apoptotic path-
way as controls.
Since the O2− produced as a result of F1F0-ATPase
inhibition is the critical signal initiating apoptosis, these
data also provide strong evidence that the OSCP, and
not another target, is responsible for mediating Bz-423
cell killing. Taken together, these studies demonstrate
that the OSCP is the molecular target of Bz-423, and
inhibition of the F1F0-ATPase is the critical event that
initiates O2− production and the subsequent apoptotic
cascade.
Discussion
1,4-benzodiazepines like diazepam are best known for
their action on the central nervous system [38]. At con-centrations above those needed for anxiolytic effects,
some benzodiazepines also affect cell survival and
growth [17]. The mechanism and target responsible for
these other activities remains obscure. Early studies
suggested that binding to the PBR, an 18 kDa trans-
membrane protein that forms part of the mitochondrial
PT pore, mediated these effects [39]. Yet more recent
work has provided cogent evidence against this hy-
pothesis [40]. While Bz-423 binds weakly to the PBR, it
is unlikely that this interaction signals apoptosis since
Bz-423 is cytotoxic to cells reported to lack the PBR
[9], and compounds with much higher affinity for the
PBR (e.g., PK11195 and diazepam [17]) do not possess
the activity of Bz-423. These observations, along with
the selectivity of Bz-423 in vivo, suggested that this
benzodiazepine had a novel cellular target.
In contrast to other F1F0-ATPase inhibitors, which
bind in either F0 (i.e., oligomycin [18]) or F1 (i.e., efra-
peptin [41] and aurovertin [42]), the Bz-423 inhibitor
binds within the peripheral stalk of the enzyme, remote
from the active site. It is likely that Bz-423 functions by
inducing/blocking a conformational change required for
substrate binding and catalysis as reflected by the
change in Km and Vmax (e.g., see Figure 2B). To validate
the OSCP as the target within cells that mediates Bz-
423-induced apoptosis, we employed RNAi to generate
cells with reduced OSCP levels. As OSCP knockdowns
in mammalian cells have not previously been reported,
we did not know a priori whether cells with reduced
OSCP levels would have significantly altered mitochon-
drial function and physiology, which would render them
an unsuitable cellular model for target validation. How-
ever, several lines of evidence suggested that it would
be possible to specifically reduce OSCP levels without
significantly altering mitochondrial structure, function,
or cellular viability.
First, the OSCP is not needed for mammalian F1 to
bind F0 [32], which predicted that F1F0-ATPase subunits
would be expressed and assemble properly with or
without the OSCP. Second, the MMP is derived from
several sources, including activity of the MRC enzymes
and proton conduction through F0. However, expres-
sion of MRC complexes and passive proton conduction
through F0 do not require the presence of the OSCP
[32], which predicted that OSCP reduction should not
significantly alter the MMP. Last, the mitochondrial ma-
chinery required for oxidative phosphorylation is pre-
sent in “biochemical excess” [43, 44]. This means that
the oxidative phosphorylation system can compensate
for a defect in one component by upregulating other
parts of the system; it is only after the defect bypasses
a critical threshold that a change in respiration or viabil-
ity becomes apparent. For example, the F1F0-ATPase
from rat heart must be inhibited >80% before an effect
on respiration can be measured [45].
Based on these considerations, our data indicate
that, in the δOSCP clones, F1F0-ATPase complexes (±
OSCP) and MRC enzymes are expressed and assem-
bled properly. All F1F0-ATPase complexes allow dissi-
pation of the proton gradient produced by the MRC,
which prevents the MMP from becoming hyperpolar-
ized. Only the F1F0-ATPases that have the OSCP are
capable of synthesizing ATP that the cells need to sur-
vive, but the clones compensate for the fact that they
have fewer complexes with OSCP by upregulating the
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492Figure 6. Mechanism of Bz-423-Induced Cell Death in δOSCP Clones
(A) Killing of control cells (closed squares) and clones 1 (open circles) and 2 (open triangles) by Bz-423 and other cytotoxic drugs as measured
by PI permeability.
(B) Bz-423 produces a dose-dependent increase in O2− in control cells (closed squares) and clones 1 (open squares) and 2 (open triangles).
(C) Dependence of apoptosis on O2− in control cells and δOSCP clones. DHE fluorescence was measured at 1 hr and PI permeability at 24
hr. Top: plot of cell death versus O2− as a function of increasing [Bz-423] (9–12 M) for control cells (closed squares) and clone 1 (open
circles). Middle/bottom: After preincubation with vitamin E (VE; 100 M) or MnTBAP (Mn; 100 M), Bz-423 (15 M) was added to the cultures;
DHE fluorescence was measured at 1 hr (middle) and PI permeability at 24 hr (bottom): control cells (white bars), clones 1 (black bars) and 2
(gray bars).
Error bars represent the standard deviation from at least three separate determinations.
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493activity of the MRC (unpublished data). These conclu-
sions explain why the δOSCP clones have similar num-
bers of mitochondria, MMPs, levels of other F1F0-
ATPase subunits, and mitochondrial ultrastructures as
the control cells.
Many inhibitors of the F1F0-ATPase, like oligomycin,
are natural products, very potent, and extremely toxic
[46]. For example, the LD33 for oligomycin in rats is 0.5
mg/kg [47]. Although cells treated with oligomycin gen-
erate ROS as a result of a state 3 to 4 transition like
Bz-423, they also become depleted of ATP and die via
necrosis, as apoptosis can only occur with sufficient
ATP reserves [48]. In contrast, Bz-423-treated mice
show no adverse toxicities [8, 9], and when cells are
cultured with Bz-423, they exhibit a limited drop in ATP
(see Figure 4B) and die via apoptosis. For Bz-423, it is
the O2− generated as a result of the state 3 to 4 transi-
tion that is the critical signal for initiating cell death.
Thus, inhibition of the F1F0-ATPase with Bz-423 com-
pared to oligomycin has distinct functional con-
sequences that likely result from differences in the
mechanisms of inhibition. Preliminary analysis of the in-
hibition kinetics (see Figure 2B) suggests that these dif-
ferences may arise due to disparities in the enzyme-
substrate complexes each compound binds to during
the stages of the catalytic cycle (unpublished data).
A unique property of Bz-423 is its selective cytotoxic-
ity against activated, autoimmune lymphocytes in vivo
[8, 9]. Integrating knowledge of the target of Bz-423
with the properties of autoreactive lymphocytes pro-
vides a starting point to explain aspects of this selectiv-
ity. For example, lupus lymphocytes have been shown
to have 50% more mitochondria than normal immune
cells [12], and these mitochondria have lower [ATP], el-
evated ROS, less glutathione (GSH), and are hyperpo-
larized compared to normal mitochondria [13, 14]. The
exact cause of these abnormalities is not yet clear, al-
though several lines of evidence suggest that they stem
from metabolic stress, which is a consequence of the
increased energy demand imposed by persistent lym-
phocyte hyperactivation (a characteristic of human and
murine lupus), along with possible defects in the F1F0-
ATPase itself [13, 14]. Both metabolic stress and F1F0-
ATPase defects lead to hyperpolarization of ψm, and
when ψm values rise to >140 mV, excess O2− is gener-
ated by the MRC [43] and GSH is consumed. Thus, the
combination of having more mitochondria (with OSCP
target), along with altered mitochondrial bioenergetics,
ψm, and redox balance, should specifically render lu-
pus lymphocytes sensitive to Bz-423-induced apopto-
sis. Consistent with this line of reasoning, experimen-
tally reducing levels of GSH sensitizes cells to Bz-423
(unpublished data).
Previous work has demonstrated that pathways of B
cell receptor (BCR)-mediated lymphocyte activation in-
teract with Bz-423-induced signals to produce a syner-
gistic death response [26], which may also help to ex-
plain why hyperactivated lupus lymphocytes are
particularly sensitive to Bz-423. Although the specific
point of intersection of these pathways is still being elu-
cidated, calcium is an essential component of the re-
sponse [26]. Mitochondria play a central role in modu-
lating intracellular Ca2+ fluxes, and Ca2+ can both
stimulate mitochondrial metabolism and ATP prod-uction, as well as exert control over mitochondrial apo-
ptosis through the PT pore [49, 50]. The magnitude and
duration of Ca2+ signals are particularly important for
determining the net effect a given signal will have on
the mitochondria. A transient Ca2+ spike serves primar-
ily to increase metabolism. In contrast, a sustained
Ca2+ response of greater magnitude and duration is
thought to play a greater role in PT induction [50, 51].
While the exact amount of Ca2+ uptake needed to in-
duce the MPT is unknown, the amount of Ca2+ required
is much lower when mitochondrial levels of pyrophos-
phate and ROS are increased [52]. Thus, the exposure
of hyperactivated lupus lymphocytes to Bz-423-
induced mitochondrial ROS may be sufficient to con-
vert signals that are normally stimulatory for these
pathogenic cells (i.e., Ca2+ flux) into death-inducing
messengers.
Significance
Bz-423 is a cytotoxic 1,4-benzodiazepine that sup-
presses autoimmunity and prolongs survival in mu-
rine models of lupus by selectively killing disease-
causing lymphocytes. Unlike drugs currently used to
treat lupus, like cyclophosphamide, Bz-423 blunts au-
toimmune disease without adverse toxicity or attenu-
ation of normal immune function. Here, using phage
display screening, we demonstrated that Bz-423
binds to the OSCP component of the mitochondrial
F1F0-ATPase and validated that this target mediates
Bz-423-induced apoptosis. The Bz-423 inhibitor binds
within the peripheral stalk of the F1F0-ATPase and
compared to compounds like oligomycin, efrapeptin,
and aurovertin, which are highly toxic, has a unique
mechanism of action. Rather than significantly de-
pleting ATP, inhibition of the F1F0-ATPase by Bz-423
leads to a state 3 to 4 transition within mitochondria,
resulting in production of O2− from the respiratory
chain, which is the key signal for apoptosis initiation.
Interestingly, lupus lymphocytes have greater num-
bers of mitochondria, and these mitochondria have
elevated ROS, reduced antioxidant stores, and are hy-
perpolarized compared to normal mitochondria.
These alterations likely sensitize autoimmune lym-
phocytes to Bz-423-induced apoptosis and provide a
significant basis for the selectivity observed in vivo.
New therapies specifically for the treatment of lupus
have not been approved in over 30 years. Our data
point to a drug target and mechanism on which to
base the development of selective cytotoxic agents
with therapeutic potential for lupus and related auto-
immune diseases. Given the efficacy and favorable
toxicity profile of Bz-423, molecules with similar prop-
erties are expected to be promising leads.
Experimental Procedures
Reagents
Bz-423 was synthesized as previously described [53]. DHE,
DiOC6(3), MitoTracker Red 580, and anti-F1F0-ATPase antibodies
(α, β, d) were from Molecular Probes (Eugene, Oregon). MnTBAP
was from Alexis Biochemicals (San Diego, California). ADP and
AMP were from Calbiochem (San Diego, California). ATP, NADH,
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494NADP+, and coupling enzymes were from Roche Applied Science h
((Indianapolis, Indiana).
t
CCell Lines and Culture
aHuman embryonic kidney 293 cells (293 cells) were maintained in
DMEM and Ramos B cells were maintained in RPMI; both were
supplemented with 10% heat-inactivated FBS, penicillin (100 U/ml), E
streptomycin (100 g/ml), and L-glutamine (290 g/ml). Studies with A
drugs and inhibitors were performed as previously described [8]. a
R
TAnalysis of Cell Death and O2−
fCell viability was measured by propidium iodide (PI) exclusion and
fO2− was measured using DHE by flow cytometry as previously de-
iscribed [8].
g
bLibrary Screening
TA human breast cancer T7 cDNA phage display library (Novagen,
TSan Diego, California) was generated and screened using biotiny-
2lated-Bz-423 as previously described [15]. In brief, the library was
otitered, and 3.7 × 108 plaque forming units (pfu) of phage were
psuspended in Tris (50 mM), NaCl (0.9 M), and 0.1% Tween (TBST,
s500 l) and combined with avidin beads (200 l, Pierce, Rockford,
iIllinois) for 1 hr to remove avidin binding phage. The supernatant
(was added to fresh beads (200 l) containing biotinylated Bz-423
O(1 ml, 400 M) in PBS and agitated overnight at 4°C. The beads
dwere collected and washed and the phage was eluted. Eluted
cphage were amplified and 108–109 phage particles were used in
ueach subsequent round of selection. After the first round, the incu-
bation time was reduced to 1 hr.
A
CPreparation of Submitochondrial Particles
dMitochondria were isolated from bovine hearts [54] with 2-mercap-
ftoethanol (5 mM) in all buffers, and submitochondrial particles
u(SMPs) for ATP hydrolysis [19] and synthesis [55] assays were pre-
tpared by sonication.
s
dF1F0-ATPase Activity
vATP hydrolysis was measured in bovine SMPs by coupling the
production of ADP to the oxidation of NADH [56]. ATP synthesis
was measured by coupling the production of ATP to the reduction
Aof NADP+ [57].
WReconstitution Studies
MBovine heart F1-ATPase was isolated as described by Walker et al.
t[19]. The OSCP was expressed and purified as previously de-
tscribed [21, 58]. F1-ATPase was reconstituted with recombinant
bovine OSCP as described by Collinson et al. [21] and the complex
was isolated by gel filtration. Bovine heart SMPs were prepared at R
pH 8.6 with EDTA (2 mM), and were then sequentially depleted of R
IF1, F1, and OSCP, yielding SMPs [20]. Aliquots of SMPs from A
each depletion step were immunoblotted for IF1, β, and OSCP to P
confirm the removal of the appropriate subunits at each step.
SMPs were reconstituted with F1 alone or F1 and OSCP [20]. R
ATP Synthesis and Oxygen Consumption in Whole Cells
Ramos B cells were permeabilized with digitonin (14 g/106 cells;
1 × 107 cells/ml; 3 min), and the rates of mitochondrial ATP synthe-
sis and oxygen consumption were measured in the presence of
malate/glutamate substrates as previously described [29, 30], with
the exception that bovine serum albumin was excluded from the
measurement buffer. For ATP synthesis, the luciferase-luciferin as-
say was monitored continuously over 30 min using a 96-well plate-
reading luminometer, and synthetic rates were evaluated over a
time frame in which the ATP synthetic rate was linear. Relative lumi-
nescence units (RLU) were converted to [ATP] using an ATP stan-
dard curve. A Hansatech oxygen electrode and Oxygraph software
were used for monitoring and analyzing oxygen consumption.
Transfection with Small Interfering RNAs To Reduce OSCP
RNA oligonucleotide duplexes (21 bp long), complimentary to re-
gions within the OSCP mRNA, designated siRNA 1 (AAG CCT AAA
TGA CAT CAC AGC) and siRNA 2 (AAG TGT TGG TTT TCT GCC
ATC), and a 19 bp long control RNA sequence not present in theuman genome (ACT ACC GTT GTT ATA GGT G) were obtained
Dharmacon; Boulder, Colorado). 293 cells were transfected with
he siRNAs (200 nM) using Oligofectamine (Invitrogen; San Diego,
alifornia) and screened for OSCP expression by immunoblotting
t indicated time points.
stablishing OSCP siRNA Stable Transfectants
pGEM1 plasmid containing the human U6 gene locus was used
s the template to PCR amplify a 350 bp long fragment of the U6
NA promoter with primer pairs: ACGGTAATACGACTCACTA
AGGG and CTACGTCGACCGACGGCCAGTGCCAAGCTT. This
ragment was cloned into pEGFP-N1 (Clontech, San Diego, Cali-
ornia) immediately 5# of the CMV promoter. The resulting construct
s designated pEGFP-N1-U6. To reduce OSCP expression, an oli-
onucleotide containing a 19 bp long inverted repeat (underlined
elow) complimentary to the human OSCP mRNA, GATTCCGTG
TGGTTTTCTGCCATCTTCAAGAGAGATGGCAGAAAACCAACAC
TTTTTG, was cloned into pEGFP-N1-U6 (designated p-iOSCP).
93 cells were transfected using Oligofectamine with this plasmid
r a vector control containing a sequence of identical length not
resent in the human genome. After transfection (48 hr), cells were
orted by flow cytometry on the basis of GFP fluorescence and
ndividual clones were expanded in the presence of geneticin
G418; 1.5 mg/ml). Of eleven clones, two had significantly reduced
SCP expression as determined by immunoblotting followed by
ensitometry quantification. Mitochondria were isolated from the
lones [55] and immunoblotted for levels of other F1F0-ATPase sub-
nits (α, β, d).
nalysis Mitochondria in Stable Transfectants
ells were grown on chamber slides and loaded with complete me-
ium containing DiOC6(3) (20 nM) and MitoTracker Red 580 (50 nM)
or 30 min at 37°C. Cells were washed with PBS and examined
sing an MRC-600 laser scanning confocal microscope. For quanti-
ative analysis of mitochondria by flow cytometry, cells were
tained as described above, and mean fluorescence intensity was
etermined. Electron microscopy samples were prepared as pre-
iously described [59] and viewed on a Philips CM100 at 60kV.
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